why choose us

First received: July 11, 2023

Clinical Trial: A Study of Zipalertinib and Chemotherapy Compared With Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion.

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

Study Type: INTERVENTIONAL


Official Title: Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untr

Brief Summary: The purpose of this study is to will evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.

Read more